Table 3.

GMCs of anti-PRP antibodies post-primary, pre-booster, and post-booster by country. (per protocol set).

	Germany		Italy		Spain
	N	GMC (95% CI) µg/mL	N	GMC (95% CI) µg/mL	N	GMC (95% CI) µg/mL
Post-primary
Ih group	58	0.5 (0.4–0.8)	8	0.2 (0.1–0.8)	147	0.5 (0.4–0.7)
Va group	66	6.9 (4.7–10.2)	8	19.6 (10.0–38.5)	156	13.5 (10.8–16.7)
Pre-booster
Ih group	61	0.2 (0.1–0.2)	7	0.1 (0.0–0.4)	138	0.3 (0.2–0.3)
Va group	67	1.4 (0.9–2.0)	10	3.2 (1.7–6.0)	139	2.1 (1.7–2.6)
Post-booster
Ih group	62	7.5 (5.2–10.6)	8	4.1 (1.1–16.0)	141	15.6 (12.8–19.1)
Va group	67	8.1 (5.6–11.8)	10	31.8 (16.8–60.2)	141	15.1 (12.2–18.7)

The per protocol set includes all study participants who received all study vaccinations and complied with all study related interventions and conditions as defined in the study protocol.

Ih group: study participants receiving DTPa HBV IPV/Hib vaccine; Va group: study participants receiving DTaP5 HB IPV Hib vaccine.

CI, confidence interval; GMC, geometric mean concentration; N, number of participants with available results; PRP, polyribosylribitol phosphate.